Updated: CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations

Another GLP-1 drug is up for Medicare negotiations under the Inflation Reduction Act. Eli Lilly’s diabetes drug Trulicity is among 15 drugs selected for the third round of negotiations. For the ...